Evofem Biosciences Inc
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
EVFM$0.48-23.4%Stored close · as of Aug 10, 2022
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three months ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $956 | $(4,809) |
| Adjustments to reconcile net income (loss) to net cash, cash equivalents and restricted cash provided by operating activities: | ||
| Loss on issuance of financial instruments | - | 3,275 |
| Gain on debt extinguishment | - | (1,120) |
| Change in fair value of financial instruments | (1,221) | (802) |
| Inventory write-down for excess & obsolescence | 178 | - |
| Loss on contingent liability | 25 | - |
| Stock-based compensation | 70 | 237 |
| Depreciation | 6 | 12 |
| Amortization of intangible asset | 223 | - |
| Noncash interest expense | 577 | 564 |
| Noncash right-of-use amortization | 37 | 47 |
| Net loss on disposal or impairment of property and equipment | 17 | 5 |
| Gain on accounts payable and accrued expenses settlements | (5,607) | - |
| Changes in operating assets and liabilities: | ||
| Trade accounts receivable | 8,683 | 1,432 |
| Inventories | (864) | 391 |
| Prepaid and other assets | 107 | 573 |
| Accounts payable | (1,776) | (726) |
| Accrued expenses and other liabilities | 34 | 438 |
| Accrued compensation | (849) | 652 |
| Operating lease liabilities | (36) | (46) |
| Net cash, cash equivalents and restricted cash provided by operating activities | 560 | 123 |
| Cash flows from investing activities: | ||
| Payments related to asset acquisition | (57) | - |
| Purchases of property and equipment | - | (14) |
| Net cash, cash equivalents and restricted cash used in investing activities | (57) | (14) |
| Cash flows from financing activities: | ||
| Payments under short term debt and Notes – carried at fair value | (135) | - |
| Net cash, cash equivalents and restricted cash used in financing activities | (135) | - |
| Net change in cash, cash equivalents and restricted cash | 368 | 109 |
| Cash, cash equivalents and restricted cash, beginning of period | 741 | 580 |
| Cash, cash equivalents and restricted cash, end of period | $1,109 | $689 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Purchases of property and equipment included in accounts payable and accrued expenses | $78 | $78 |
| Series E-1 Shares deemed dividends | 3 | 47 |
| Issuance of common stock upon exercise of purchase rights | - | 89 |
| Issuance of common stock upon conversion of notes | - | 35 |
| Issuance of common stock upon exercise of warrants | - | 15 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.